This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Dentsply International (XRAY) Misses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Dentsply (XRAY) delivered earnings and revenue surprises of -3.80% and 3.59%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Select Medical (SEM) Beats Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Select Medical (SEM) delivered earnings and revenue surprises of 27.59% and 0.07%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Staar Surgical (STAA) Q4 Earnings Top Estimates
by Zacks Equity Research
Staar Surgical (STAA) delivered earnings and revenue surprises of 18.75% and 0.50%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Patterson Cos. (PDCO) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Patterson Cos. (PDCO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why You Should Retain Patterson Companies (PDCO) Stock
by Zacks Equity Research
Patterson Companies (PDCO) continues to benefit from strength in the Animal Health business and dental business.
Here's Why You Should Hold on to Illumina (ILMN) for Now
by Zacks Equity Research
Investors are optimistic about Illumina (ILMN) owing to its strength in international markets and notable strategic partnerships.
Alcon (ALC) Launches Preservative-Free Drops for Dry Eye Relief
by Zacks Equity Research
Alcon's (ALC) new preservative-free solution for patients with dry eye symptoms is the latest addition to its leading global artificial tear brand Systane.
Integra (IART) Announces Preliminary Q4 & '21 Sales Results
by Zacks Equity Research
Integra's (IART) preliminary revenue results and recent plans to implement a $125-million share repurchase instill investor optimism.
Cardiovascular Systems (CSII) Coronary Sales Up Amid COVID Woe
by Zacks Equity Research
Cardiovascular Systems (CSII) continues to experience strong demand for physician training and certification in all international markets.
Hologic (HOLX) Up on Preliminary Q1 Organic Sales Growth
by Zacks Equity Research
Hologic's (HOLX) Diagnostics division's preliminary numbers show a strong rebound in the base business.
Here's Why You Should Hold on to Align Technology (ALGN) Now
by Zacks Equity Research
Investors are optimistic about Align Technology (ALGN) given huge market potential in its Invisalign brand and strategic partnerships.
Medtronic (MDT) Gets MHLW Approval for Micra AV Sale in Japan
by Zacks Equity Research
The Micra AV approval is likely to boost Medtronic's (MDT) Cardiac Rhythm Management business while delivering the benefits of leadless pacing in Japan.
Illumina (ILMN) Announces Preliminary Q4 Sales, Issues '22 View
by Zacks Equity Research
Illumina's (ILMN) preliminary fourth-quarter results, latest partnership deals and a robust pipeline of technologies instill investor optimism.
IDEXX's (IDXX) Low LPD Sales, Rise in Expenses Dampen Growth
by Zacks Equity Research
Distributor purchasing dynamics have an impact on IDEXX's (IDXX) reported sales of CAG products.
Medtronic (MDT) to Buy Affera, Expand in Electrophysiology
by Zacks Equity Research
Affera's full suite of solutions and technologies will complement Medtronic's (MDT) existing atrial and ventricular arrhythmia disease management portfolio.
PDCO vs. CNMD: Which Stock Is the Better Value Option?
by Zacks Equity Research
PDCO vs. CNMD: Which Stock Is the Better Value Option?
Here's Why You Should Retain Patterson Companies (PDCO) Stock
by Zacks Equity Research
Patterson Companies (PDCO) continues to benefit from strength in Animal Health business and dental business.
PDCO or CNMD: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
PDCO vs. CNMD: Which Stock Is the Better Value Option?
Patterson Companies (PDCO): The Perfect Mix of Value and Rising Earnings Estimates?
by Zacks Equity Research
Patterson Companies (PDCO) seems to be a good value pick, as it has decent revenue metrics to back up its earnings, and is seeing solid earnings estimate revisions as well.
After Plunging 15.7% in 4 Weeks, Here's Why the Trend Might Reverse for Patterson Cos. (PDCO)
by Zacks Equity Research
Patterson Cos. (PDCO) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Patterson Cos. (PDCO) Moves to Buy: Rationale Behind the Upgrade
by Zacks Equity Research
Patterson Cos. (PDCO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
PDCO vs. CNMD: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
PDCO vs. CNMD: Which Stock Is the Better Value Option?
Patterson Companies (PDCO) Beats on Q2 Earnings & Revenues
by Zacks Equity Research
Patterson Companies' (PDCO) fiscal second-quarter 2022 results benefit from strength in the Animal Health segment.
Patterson Cos. (PDCO) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Patterson Cos. (PDCO) delivered earnings and revenue surprises of 16% and 4.24%, respectively, for the quarter ended October 2021. Do the numbers hold clues to what lies ahead for the stock?
What's in Store for Patterson Companies' (PDCO) Q2 Earnings?
by Zacks Equity Research
Patterson Companies' (PDCO) fiscal second-quarter results are likely to reflect improvement at Dental segment.